DeepMed Research

EMD SERONO

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Placebo
Biological: Tecemotide (L-BLP25)
Drug: Single low dose cyclophosphamide

First Posted Date: 2006-12-08

Last Posted Date: 2015-11-20

Lead Sponsor: EMD Serono

Target Recruit Count: 1513

Registration Number: NCT00409188

Locations: 🇺🇸
Deaconess Billings Clinic, Billings, Montana, United States
🇺🇸
University of Maryland, Marlene and Steward Greenbaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

and more 90 locations

ATS-1 Needle Free Injection Device Study-a Device for Administering r-hGH (Saizen) to Treat Growth Hormone Deficiency

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2006-12-05

Last Posted Date: 2013-10-22

Lead Sponsor: EMD Serono

Target Recruit Count: 38

Registration Number: NCT00407472

AS703569 Phase I in Patients With Solid Tumours

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: AS703569

First Posted Date: 2006-10-24

Last Posted Date: 2014-01-30

Lead Sponsor: EMD Serono

Target Recruit Count: 104

Registration Number: NCT00391521

Locations: 🇺🇸
EMD Serono Medical Information Office, Rockland, Massachusetts, United States

Rebif® Pregnancy Registry

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2006-06-20

Last Posted Date: 2013-08-05

Lead Sponsor: EMD Serono

Target Recruit Count: 36

Registration Number: NCT00338741

Locations: 🇺🇸
Local Medical Information Office, Rockland, Massachusetts, United States

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

Phase 4

Terminated

Conditions: Hypogonadotropic Hypogonadism

Interventions: Drug: Luveris® 25 IU
Drug: Luveris® 75 IU
Drug: Placebo
Drug: Recombinant human follicle stimulating hormone (r-hFSH)
Drug: Recombinant human chorionic gonadotropin (r-hCG)

First Posted Date: 2006-05-24

Last Posted Date: 2013-08-07

Lead Sponsor: EMD Serono

Target Recruit Count: 11

Registration Number: NCT00328926

Locations: 🇺🇸
U.S. Medical Information, 1-888-275-7376, Rockland, Massachusetts, United States

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Phase 2

Completed

Conditions: Parkinson's Disease
Dyskinesia

First Posted Date: 2006-04-13

Last Posted Date: 2017-01-23

Lead Sponsor: EMD Serono

Target Recruit Count: 360

Registration Number: NCT00314288

Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

First Posted Date: 2006-03-17

Last Posted Date: 2013-08-06

Lead Sponsor: EMD Serono

Target Recruit Count: 192

Registration Number: NCT00304252

Locations: 🇬🇧
Medical Information Office, Feltham, United Kingdom

Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Interferon-beta-1a, 44 microgram
Drug: Interferon-beta-1a, 66 microgram

First Posted Date: 2006-03-16

Last Posted Date: 2013-08-06

Lead Sponsor: EMD Serono

Target Recruit Count: 194

Registration Number: NCT00303381

Locations: 🇬🇧
Research Site, Feltham, United Kingdom

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

Phase 4

Completed

Conditions: Infertile Women Undergoing Assisted Reproductive Technology (ART)

Interventions: Drug: Cetrotide®
Drug: Antagon ™
Drug: Recombinant human follicle stimulating hormone (r-hFSH)
Drug: Human Menopausal Gonadotropin (hMG)
Drug: Recombinant Human Choriogonadotropin (r-hCG)

First Posted Date: 2006-03-01

Last Posted Date: 2014-03-26

Lead Sponsor: EMD Serono

Target Recruit Count: 185

Registration Number: NCT00298025

An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome

Phase 2

Completed

Conditions: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Human Immunodeficiency Virus Infections

Interventions: Drug: Serostim®

First Posted Date: 2006-02-22

Last Posted Date: 2014-03-26

Lead Sponsor: EMD Serono

Target Recruit Count: 142

Registration Number: NCT00294918

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy